<scp>UVA</scp>‐1 phototherapy for the management of atopic dermatitis: a large retrospective study conducted in a low‐middle income country

Rubiano, María Fernanda Ordóñez; Arenas, Claudia Marcela; Chalela, Juan Guillermo

doi:10.1111/ijd.14011

Cited by 12 publications

(9 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Las más recomendadas para dermatitis atópica son la RUV B de banda estrecha (UVB-NB) y la RUV-A1 (UVA1) (28)(36) (43). En general se recomienda el uso de UVB-NB para el manejo de lesiones crónicas mientras que de UVA1 para las lesiones agudas, aunque hay estudios que sugieren que UVA1 también genera buena respuesta en pacientes con lesiones crónicas (44).…”

Section: Fototerapiaunclassified

Phototherapy for atopic dermatitis

Rodenbeck

Silverberg

2016

Clinics in Dermatology

View full text Add to dashboard Cite

Section: Fototerapiaunclassified

Phototherapy for atopic dermatitis

Rodenbeck

Silverberg

2016

Clinics in Dermatology

View full text Add to dashboard Cite

“…Regarding severe atopic dermatitis, the role of UVA1 phototherapy in treatment is well established [ 26 , 27 , 28 , 29 ]. A systematic review [ 30 ] of nine randomized trials found that, in adult patients with acute, severe atopic dermatitis, phototherapy with UVA1 was faster than that with conventional UVA/UVB in inducing clinical improvement, with a peak response after 10 treatments.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Satisfaction of Low Doses UVA1 Phototherapy: A Spanish Experience from a Single Centre

Velasco-Amador

Linares‐González

Gomar

2023

Life

View full text Add to dashboard Cite

Background: UVA1 phototherapy is a treatment used for multiple dermatological conditions. The optimal therapeutic regimens and dosing of UVA1 are a matter of debate. The dosages used vary widely between published studies and there are no evidence-based protocols that provide data on dosage, duration, or the role of maintenance therapy. The purpose of this study is to evaluate the experience in our medical center regarding treatment with UVA1, as well as the degree of patient satisfaction with the treatment according to their pathology. Methods: We present a retrospective evaluation of outcomes, treatment tolerability, and satisfaction in adult patients using a low dose of UVA1 phototherapy, administered in our dermatologic service between 2019 and 2022. Results: A total of 78 patients were treated with UVA1, of whom 46 patients (59%) were over 18 years old, completed treatment, and gave their consent. The overall objective clinical response rate was 91.30% (42/46), achieving a complete response in 17 (36.96%) patients, partial response in 25 (54.34%), and no response in 4 (8.70%). The complete response rates recorded were high in morphea, scleredema, or chronic hand eczema. In terms of the level of satisfaction objectively measured by TSQM-9 version 1.4, highlighting high scores obtained in mastocytosis, systemic sclerosis, morphea, scleredema, chronic hand eczema, or prurigo nodularis (over 65 points). Conclusions: We present a review of treatment with UVA1 phototherapy at low doses with good response in a wide variety of dermatological pathologies.

show abstract

“…Ultraviolet (UV) phototherapy has been recommended as a treatment option for AD cases that are refractory to basic care and topical therapies [ 104 , 118 ]. Importantly, UVA-1 and narrowband UVB (NB–UVB) are the most effective treatment modalities for improving clinical signs of AD [ 119 , 120 ]. Interestingly, low-dose UVB irradiation was reported to increase AMP expression and improve barrier recovery in the murine epidermis [ 121 ].…”

Section: Influence Of Ad Treatments On Ampsmentioning

confidence: 99%

Role of Antimicrobial Peptides in Skin Barrier Repair in Individuals with Atopic Dermatitis

Nguyen

Trujillo-Paez

Umehara

et al. 2020

IJMS

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a common chronic inflammatory skin disease that exhibits a complex interplay of skin barrier disruption and immune dysregulation. Patients with AD are susceptible to cutaneous infections that may progress to complications, including staphylococcal septicemia. Although most studies have focused on filaggrin mutations, the physical barrier and antimicrobial barrier also play critical roles in the pathogenesis of AD. Within the physical barrier, the stratum corneum and tight junctions play the most important roles. The tight junction barrier is involved in the pathogenesis of AD, as structural and functional defects in tight junctions not only disrupt the physical barrier but also contribute to immunological impairments. Furthermore, antimicrobial peptides, such as LL-37, human b-defensins, and S100A7, improve tight junction barrier function. Recent studies elucidating the pathogenesis of AD have led to the development of barrier repair therapy for skin barrier defects in patients with this disease. This review analyzes the association between skin barrier disruption in patients with AD and antimicrobial peptides to determine the effect of these peptides on skin barrier repair and to consider employing antimicrobial peptides in barrier repair strategies as an additional approach for AD management.

show abstract

UVA‐1 phototherapy for the management of atopic dermatitis: a large retrospective study conducted in a low‐middle income country

Cited by 12 publications

References 9 publications

Phototherapy for atopic dermatitis

Phototherapy for atopic dermatitis

Efficacy and Satisfaction of Low Doses UVA1 Phototherapy: A Spanish Experience from a Single Centre

Role of Antimicrobial Peptides in Skin Barrier Repair in Individuals with Atopic Dermatitis

Contact Info

Product

Resources

About